Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

meningococcal C and Y/haemophilus influenza type B vaccine (Rx)Brand and Other Names:MenHibrix

 
 
 

Dosing & Uses

AdultPediatric

This product is not indicated in adult patients

Dosage Forms & Strengths

Injectable lyophilized vaccine supplied as single-dose vial to be reconstituted with accompanying saline

IM solution

  • 0.5mL/vial (reconstituted dose)
more...

Immunization

Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b in children aged 6 weeks through 18 months

4-dose regimen (not for routine vaccination); use only for HIB immunization in infants at high risk for meningococcal infection)

0.5 mL IM at 2, 4, 6, and 12-15 months

The 1st dose may be initiated as early as 6 weeks old; the 4th dose may be given as late as 18 months old

Immunization for High-Risk Conditions (ACIP Guidelines)

Asplenia

  • Indicated for children with anatomic or functional asplenia (including sickle cell disease)
  • 4 dose infant series administered at 2, 4, 6, and 12 through 15 months of age
  • Booster dose: Every 5 years with Menveo or Menactra

Complement deficiency

  • Indicated for children with persistent complement component deficiency
  • 4-dose infant series administered at 2, 4, 6, and 12 through 15 months of age
  • Booster dose: Every 5 years with Menveo or Menactra

Community outbreak

  • For children at risk during a community outbreak attributable to a vaccine serogroup, administer or complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo

Dosing Considerations

Travel/reside in hyperendemic/epidemic countries: Prior receipt of MenHibrix is not sufficient for children traveling to the African meningitis belt or the Hajj because it does NOT contain serogroups A or W

Administration

For IM use only

Infants <1 years: Preferred injection site is the anterolateral aspect of the thigh

Age ≥ 1 year: May receive the vaccine in the deltoid muscle

Next

Interactions

Interaction Checker

meningococcal C and Y/haemophilus influenza type B vaccine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Pain, any (41.4-46.2%)

            Redness (20.6-34.6%)

            Swelling at injection site >30 mm (14.7-25.4%)

            Irritability (62.1-70.8%)

            Drowsiness (48.7-62.8%)

            Loss of appetite (30.1-33.8%)

            Fever ≥100.4 degrees Fahrenheit (11-25.9%)

            1-10%

            Fever ≥102.2 degrees Fahrenheit (1.1 – 3.2%)

            Postmarketing Reports

            Administration site: Extensive swelling of vaccinated limb, injection site induration

            Immune system: Allergic reaction, anaphylaxis, angioedema

            Nervous System: Convulsions with or without fever, hypotonic-hyporesponsive episode, somnolence, syncope, or vasovagal response

            Respiratory: Apnea

            Skin: Rash, urticaria

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to vaccine or any of its components

            Patients that experienced severe allergic reactions (eg, anaphylaxis) after administration of H. influenzae type b-, meningococcal-, or tetanus toxoid-containing vaccine

            Cautions

            Guillain-Barre syndrome has occurred within 6 weeks prior to vaccine containing tetanus toxoid

            Syncope reported in association with injectable vaccines and is accompanied by paresthesia, tonic-clonic limb movements, and/ or visual disturbances may occur

            Premature infants are at higher risk of developing apnea following IM vaccination; consider medical status and weigh potential benefits and risks to determine about when to administer the vaccine

            Review immunization history for potential hypersensitivity reactions; epinephrine and other agents must be readily available should an anaphylactic reaction occur

            Safety and effectiveness have not been evaluated in immunosuppressed patients; expected immune response may not be obtained

            Patients must continue to receive routine tetanus immunization as MenHibrix is not a substitution

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown whether distributed in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Contains antigenic capsular polysaccharides (ie, meningococcal serogroups A and C, Haemophilus influenzae type b) that convey active immunity by stimulating endogenous antibody production; antibodies have been associated with protection from invasive meningococcal disease

            Previous
            Next

            Administration

            IM Preparation

            Clean both vial stoppers (lyophilized vaccine and diluent)

            Withdraw 0.6 mL of saline from diluent vial and transfer to lyophilized vaccine vial

            Shake vial well

            Reconstitute single-dose vial containing lyophilized vaccine only with accompanying vial of saline diluent

            Reconstituted solution should be clear and colorless

            Withdraw 0.5 mL of reconstituted vaccine in syringe for IM administration

            IM Administration

            Visually inspect for particulate matter and discoloration before administration, if either of these conditions exist do not administer

            For IM injection only; do not administer IV, SC, or intradermally

            Use a separate sterile needle and sterile syringe for each individual

            Preferred administration site is the anterolateral aspect of the thigh for most infants aged <1 year

            Older children may receive the vaccine in the deltoid muscle

            Storage

            Before reconstitution

            • Lyophilized vaccine vials: Store refrigerated between 2-8°C (36-46°F); protect from light
            • Diluent: Store refrigerated or at controlled room temperature between 2-25°C (36-77°F); do not freeze (discard diluent if it has been frozen)

            After reconstitution

            • Administer immediately following reconstitution
            • Do not freeze
            • Discard if the vaccine has been frozen
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.